San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Hims & Hers' stock price has swung wildly this year. The telehealth company's public feud with drugmaker Novo Nordisk knocked off a nearly a third of its valuation on Monday. On Friday, Hims ...

Hims & Hers Health and Novo Nordisk announced a partnership a few months ago, and it has already come to an end. Novo Nordisk ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...

Dudum, Hims & Hers chief executive, said on social media site X that the telehealth provider would still provide a variety of treatments including Wegovy.

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...